Table 1. Characteristics of Patients .... | American Society of Hematology

Table 1.

Characteristics of Patients

	CLB 1996 (n = 1,051)		CLB 1997 (n = 312)		ELYPSE 1 (n = 295)		CLB-NHL (n = 149)		Total (n = 1,807)
	No. of Patients	%	No. of Patients	%	No. of Patients	%	No. of Patients	%	No.	%
Median age (range)	55 (18-86)		56 (18-85)		58 (18-86)		70 (27-93)
Age (yr)
<60	655	62	179	57	167^*	57	37	25	1,038	58
≥60	396	38	133	43	123^*	43	112	75	764	42
Sex
F	567	54	161	52	178	60	68	46	974	54
M	484	46	151	48	117	40	81	54	833	46
Diagnostic
Carcinoma
Breast	247	24	78	25	99	34	0	0	424	23
Colon-rectum	96	9	16	5	50	17	0	0	162	9
Ovary	90	9	14	5	32	11	0	0	136	8
Head and neck	103	10	20	6	20	7	0	0	143	8
Other gastrointestinal	112	11	18	5	11	4	0	0	141	8
Lung cancer	61	6	22	7	8	3	0	0	91	5
Lymphoma	93	9	37	12	21	7	149	100	300	17
Bone and soft tissue sarcoma	68	7	17	5	13	4	0	0	98	5
Germ cells tumors	32	3	15	5	7	2	0	0	54	3
Others	149	14	75	25	34	10	0	0	258	14
High-risk chemotherapy^-151
Yes	105	10	92	29	24	8	74	50	295	16
No	946	90	220	71	271	92	75	50	1,512	84
Chemotherapy regimens
ACVBP/ECVBP	14	1	14	4	4	1	74	50	106	6
ADRIAMYCINE alone	27	3	13	4	0	0	0	0	40	2
CDDP-5FU	85	8	15	5	16	5	0	0	116	6
CDDP-NAV/CDDP-VP16	55	5	22	7	7	2	0	0	84	5
DHAP	24	2	7	2	0	0	0	0	31	2
FAC/FEC/AC	115	11	44	14	90	28	0	0	249	14
FUFOL/LV5FU2	71	7	14	5	47	15	0	0	132	7
MAID	11	1	7	2	2	1	0	0	20	1
mBACOD	0	0	0	0	0	0	15	10	15	1
TAXANES	124	12	29	9	29	9	0	0	182	10
CHOP	25	2	12	4	9	3	53	36	99	5
BEP/EP	30	3	17	5	7	2	0	0	54	3
NAVELBINE alone	74	7	15	5	0	0	0	0	89	5
CAP/CEP/CP	34	3	2	1	22	7	0	0	58	3
Other	362	34	101	36	71	24	7	5	541	30
No. of chemotherapy course
1	766^-152	78	306	98	130	44	149	100	1,351	78
≥2	213^-152	22	6	2	165	56	0	0	384	21
Performance status
0-1	881	84	250	80	252	85	103	69	1,486	82
>1	170	16	62	20	43	15	46	31	321	18

	CLB 1996 (n = 1,051)		CLB 1997 (n = 312)		ELYPSE 1 (n = 295)		CLB-NHL (n = 149)		Total (n = 1,807)
	No. of Patients	%	No. of Patients	%	No. of Patients	%	No. of Patients	%	No.	%
Median age (range)	55 (18-86)		56 (18-85)		58 (18-86)		70 (27-93)
Age (yr)
<60	655	62	179	57	167^*	57	37	25	1,038	58
≥60	396	38	133	43	123^*	43	112	75	764	42
Sex
F	567	54	161	52	178	60	68	46	974	54
M	484	46	151	48	117	40	81	54	833	46
Diagnostic
Carcinoma
Breast	247	24	78	25	99	34	0	0	424	23
Colon-rectum	96	9	16	5	50	17	0	0	162	9
Ovary	90	9	14	5	32	11	0	0	136	8
Head and neck	103	10	20	6	20	7	0	0	143	8
Other gastrointestinal	112	11	18	5	11	4	0	0	141	8
Lung cancer	61	6	22	7	8	3	0	0	91	5
Lymphoma	93	9	37	12	21	7	149	100	300	17
Bone and soft tissue sarcoma	68	7	17	5	13	4	0	0	98	5
Germ cells tumors	32	3	15	5	7	2	0	0	54	3
Others	149	14	75	25	34	10	0	0	258	14
High-risk chemotherapy^-151
Yes	105	10	92	29	24	8	74	50	295	16
No	946	90	220	71	271	92	75	50	1,512	84
Chemotherapy regimens
ACVBP/ECVBP	14	1	14	4	4	1	74	50	106	6
ADRIAMYCINE alone	27	3	13	4	0	0	0	0	40	2
CDDP-5FU	85	8	15	5	16	5	0	0	116	6
CDDP-NAV/CDDP-VP16	55	5	22	7	7	2	0	0	84	5
DHAP	24	2	7	2	0	0	0	0	31	2
FAC/FEC/AC	115	11	44	14	90	28	0	0	249	14
FUFOL/LV5FU2	71	7	14	5	47	15	0	0	132	7
MAID	11	1	7	2	2	1	0	0	20	1
mBACOD	0	0	0	0	0	0	15	10	15	1
TAXANES	124	12	29	9	29	9	0	0	182	10
CHOP	25	2	12	4	9	3	53	36	99	5
BEP/EP	30	3	17	5	7	2	0	0	54	3
NAVELBINE alone	74	7	15	5	0	0	0	0	89	5
CAP/CEP/CP	34	3	2	1	22	7	0	0	58	3
Other	362	34	101	36	71	24	7	5	541	30
No. of chemotherapy course
1	766^-152	78	306	98	130	44	149	100	1,351	78
≥2	213^-152	22	6	2	165	56	0	0	384	21
Performance status
0-1	881	84	250	80	252	85	103	69	1,486	82
>1	170	16	62	20	43	15	46	31	321	18

*Missing data: n = 5.

See the Patients and Methods.

Missing data: n = 72.